RWA Wealth Partners LLC Has $3 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

RWA Wealth Partners LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,437 shares of the biopharmaceutical company’s stock after selling 173 shares during the quarter. RWA Wealth Partners LLC’s holdings in Gilead Sciences were worth $2,996,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Securities Group LLC boosted its holdings in shares of Gilead Sciences by 942.7% in the 4th quarter. Summit Securities Group LLC now owns 21,897 shares of the biopharmaceutical company’s stock valued at $2,023,000 after purchasing an additional 19,797 shares in the last quarter. Schroder Investment Management Group lifted its position in shares of Gilead Sciences by 14.1% during the 4th quarter. Schroder Investment Management Group now owns 2,286,141 shares of the biopharmaceutical company’s stock worth $210,348,000 after buying an additional 282,787 shares during the last quarter. Intrust Bank NA grew its position in Gilead Sciences by 10.0% in the fourth quarter. Intrust Bank NA now owns 26,764 shares of the biopharmaceutical company’s stock valued at $2,472,000 after acquiring an additional 2,435 shares during the last quarter. Allstate Corp acquired a new position in Gilead Sciences during the fourth quarter worth about $3,422,000. Finally, Maridea Wealth Management LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $496,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on GILD shares. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday. The Goldman Sachs Group upped their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley lifted their price target on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, March 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Up 0.6 %

Gilead Sciences stock opened at $111.79 on Monday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $139.22 billion, a PE ratio of 302.14, a PEG ratio of 0.71 and a beta of 0.21. The firm’s fifty day moving average is $105.48 and its 200 day moving average is $95.00. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.83%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.